Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.
Preclinical studies have identified and validated tumour necrosis factor alpha (TNFalpha) as a key disease molecule and therapeutic target for immunotherapeutic intervention in many immune-mediated inflammatory diseases. Clinical indications include rheumatoid arthritis, Crohn's disease, ankylo...
Autors principals: | Taylor, P, Williams, R, Feldmann, M |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2004
|
Ítems similars
-
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
per: Williams, R, et al.
Publicat: (2000) -
Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
per: Brennan, F, et al.
Publicat: (1995) -
What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
per: Feldmann, M
Publicat: (1996) -
Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
per: Maini, R, et al.
Publicat: (1995) -
Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.
per: Davis, D, et al.
Publicat: (1997)